42SCIENCE
⚡ Markets: A breakthrough in cancer diagnostics could be highly valuable. Positive for the developing company and potentially disruptive for existing diagnostic imaging and biopsy markets.biotech stocks
An Israeli company has developed a blood test that can reportedly detect stage 2-4 lung cancer with 93% accuracy. The test, which costs around $60, could provide a significant new tool for early cancer diagnosis if validated and commercialized.
West MSM: noneRegional 11 country
1 sources across the spectrum